New drug shows encouraging survival in pancreatic cancer
A clinical trial testing a new drug in pancreatic cancer had promising initial results, report researchers from the University of…
Read more
AZ, Merck’s latest Lynparza combo win could widen its ovarian cancer reach
In the red-hot market for PARP inhibitors, AstraZeneca and Merck’s contender Lynparza is ahead of rival products from GlaxoSmithKline and…
Study success strengthens case for Lynparza in ovarian cancer
Adding AstraZeneca’s Lynparza to Roche’s older cancer drug Avastin helped women with advanced ovarian cancer live longer without their tumors…
Novartis CEO: ‘We did the best we could’ in Zolgensma data manipulation probe
Amid a fresh scandal, this time over data manipulation for the world’s most expensive med, top Novartis execs laid out…
FDA ready to crack down as Novartis reveals manipulated Zolgensma data
Novartis’ spinal muscular atrophy gene therapy Zolgensma made all kinds of headlines leading up to and following its approval. Now, it’s making just the…
Merck and AZ pile on more positive Lynparza data in bid to break into prostate cancer
Two months back, AstraZeneca and Merck made a strong case at the American Society of Clinical Oncology (ASCO) annual meeting…
Roche trial win for Tecentriq leaves questions unanswered
Roche on Monday said its immunotherapy Tecentriq helped stave off tumor growth in a Phase 3 study of previously untreated people with…
Regulators, Gilead at odds over HIV drug’s use in women
Food and Drug Administration staff appear confident an HIV treatment developed by Gilead can also help prevent the disease from…
FDA approves first therapy for rare joint tumor
Today, the U.S. Food and Drug Administration granted approval to Turalio (pexidartinib) capsules for the treatment of adult patients with…
Bayer, Bristol-Myers Squibb and Ono Pharmaceutical enter into a clinical collaboration agreement
Bayer, Bristol-Myers Squibb Company (NYSE: BMY) and Ono Pharmaceutical Co., Ltd. (“Ono”) announced today the three companies have entered into…
